Depression and fatigue in MS patients treated with Betaferon. (FADO)
This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.
The study is conducted in routine practice setting hence no interference with standard care takes place.
Pharmacologic treatments of MS-fatigue and depression will also be recorded.
- Relapsing-remitting multiple sclerosis - Age 18+ - Patients initiating Betaferon treatment
- Patients previously treated with any immunomodulatory drug
Many Locations, Poland
E-mail: [email protected]
Phone: Not Available
The short-term effect of immunomodulatory treatment with interferon beta-1b (Betaferon) on fatigue and depression in first-time treated patients with relapsing-remitting multiple sclerosis.